Evaluation of the Fully Automated HemosIL Acustar ADAMTS13 Activity Assay

Julien Favresse; Benjamin Lardinois; Bernard Chatelain; Hugues Jacqmin; François Mullier

doi:10.1055/s-0038-1641151

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(05): 942-944
DOI: 10.1055/s-0038-1641151

Letter to the Editor

Schattauer GmbH Stuttgart

Evaluation of the Fully Automated HemosIL Acustar ADAMTS13 Activity Assay

Authors

Julien Favresse

¹Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Hematology Laboratory, NARILIS, Yvoir, Belgium
Benjamin Lardinois

¹Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Hematology Laboratory, NARILIS, Yvoir, Belgium
Bernard Chatelain

¹Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Hematology Laboratory, NARILIS, Yvoir, Belgium
Hugues Jacqmin

¹Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Hematology Laboratory, NARILIS, Yvoir, Belgium
François Mullier

¹Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Hematology Laboratory, NARILIS, Yvoir, Belgium

Abstract

Full Text

References

References
1 Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017; 129 (21) 2836-2846
2 Levy GG, Nichols WC, Lian EC. , et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855): 488-494
3 Sadler JE. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2015; 2015: 631-636
4 Mackie I, Langley K, Chitolie A. , et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 2013; 109 (03) 488-496
5 Joly B, Stepanian A, Hajage D. , et al. Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Thromb Res 2014; 134 (05) 1074-1080
6 Hie M, Gay J, Galicier L. , et al; French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 2014; 124 (02) 204-210
7 Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017; 130 (10) 1181-1188
8 Langley K, Fretwell R, Kitchen S. , et al. Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays. Int J Lab Hematol 2018; 40 (01) 21-25
9 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (01) 93-100
10 Palla R, Valsecchi C, Bajetta M, Spreafico M, De Cristofaro R, Peyvandi F. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thromb Haemost 2011; 105 (02) 381-385
11 Hubbard AR, Heath AB, Kremer Hovinga JA. ; Subcommittee on von Willebrand Factor. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (06) 1151-1153
12 Nakashima MO, Zhang X, Rogers HJ. , et al. Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test. Int J Lab Hematol 2016; 38 (05) 550-559
13 Mirabet M, Blanch S, Puig J, Serra J. Highly sensitive fully automated chemiluminescent immunoassay for rapid quantification of ADAMTS13 activity. Res Pract Thrombosis Haemostasis 2017; 1 (Suppl. 01) 1297